Satralizumab Approved for Thyroid Eye Disease

The FDA approved satralizumab for thyroid eye disease (TED), providing the first at-home subcutaneous treatment option. This approval builds on clinical trial data showing significant improvements in symptoms and adds to the growing number of immunology-based therapies available for TED.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.